Aurinia Pharmaceuticals (AUPH) Income towards Parent Company: 2014-2024
Historic Income towards Parent Company for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Dec 2024 value amounting to $5.7 million.
- Aurinia Pharmaceuticals' Income towards Parent Company rose 120.53% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 443.39%. This contributed to the annual value of $5.7 million for FY2024, which is 107.36% up from last year.
- As of FY2024, Aurinia Pharmaceuticals' Income towards Parent Company stood at $5.7 million, which was up 107.36% from -$78.1 million recorded in FY2023.
- Over the past 5 years, Aurinia Pharmaceuticals' Income towards Parent Company peaked at $5.7 million during FY2024, and registered a low of -$181.0 million during FY2021.
- For the 3-year period, Aurinia Pharmaceuticals' Income towards Parent Company averaged around -$60.2 million, with its median value being -$78.1 million (2023).
- Per our database at Business Quant, Aurinia Pharmaceuticals' Income towards Parent Company tumbled by 76.24% in 2021 and then spiked by 107.36% in 2024.
- Over the past 5 years, Aurinia Pharmaceuticals' Income towards Parent Company (Yearly) stood at -$102.7 million in 2020, then slumped by 76.24% to -$181.0 million in 2021, then skyrocketed by 40.22% to -$108.2 million in 2022, then climbed by 27.83% to -$78.1 million in 2023, then surged by 107.36% to $5.7 million in 2024.